Shilpa Gupta - Concepedia

Author

Shilpa Gupta

Also Known As

Dr. S.K. Gupta, Dr. Shilpa Gupta, Gupta, Shilpa, Nonato, Taylor K, Paari Murugan, Piyush Chaudhari, S Gupta, S. Gupta, S.K. Gupta, Shah, S.A.

550

Publications

15K

Citations

H-Index

117

Concepts

All Affiliations

Cleveland Clinic University of Washington Dana-Farber Cancer Institute Fred Hutch Cancer Center Moffitt Cancer Center

About

Shilpa Gupta is an author at Cleveland Clinic specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	67	7.6K
2	Health Sciences	12	17	442
3	Public Health	5	5	2.1K
4	Engineering	2	2	96
5	Natural Sciences	1	1	20

Shilpa Gupta

125

Publications

13.2K

Citations

H-Index

Page 1

	Year	Citations
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, The Lancet EpidemiologyCancer EpidemiologyMedicineGlobal HealthEpidemiology Of Cancer	2020	1.8K
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study Rita Nanda, Laura Q.M. Chow, Elizabeth Claire Dees, Journal of Clinical Oncology	2016	1.4K
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial Kei Muro, Hyun Cheol Chung, Veena Shankaran, The Lancet Oncology Gastrointestinal OncologyMedicinePathologyImmune Checkpoint InhibitorGastric Cancer	2016	1.1K
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort Laura Q.M. Chow, Robert I. Haddad, Shilpa Gupta, Journal of Clinical Oncology Antitumor ActivityImmunologyPathologyPharmacotherapyImmunotherapy	2016	846
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer Thomas Powles, Begoña P. Valderrama, Shilpa Gupta, New England Journal of Medicine	2024	764
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology Edward M. Schaeffer, Sandy Srinivas, Nabil Adra, Journal of the National Comprehensive Cancer Network UrologySurgical OncologyGenitourinary CancerMedicineCancer Management	2023	509
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 Ranee Mehra, Tanguy Y. Seiwert, Shilpa Gupta, British Journal of Cancer	2018	443
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study Elizabeth R. Plimack, Joaquim Bellmunt, Shilpa Gupta, The Lancet Oncology Metastatic Urothelial CancerUrologyGenitourinary CancerMedicineImmune Checkpoint Inhibitor	2017	333
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium Petros Grivas, Ali Raza Khaki, Trisha M. Wise‐Draper, Annals of Oncology	2021	321
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce Harriet M. Kluger, Hussein A. Tawbi, Maria Libera Ascierto, Journal for ImmunoTherapy of Cancer New AgentsImmunologyImmunoeditingImmunotherapyTumor Resistance	2020	260

Page 1